99 related articles for article (PubMed ID: 7371023)
1. Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans.
Erlichman C; Strong JM; Chabner BA
Cancer Res; 1980 Jun; 40(6):1902-6. PubMed ID: 7371023
[TBL] [Abstract][Full Text] [Related]
2. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
Chadwick M; Silveira DM; MacGregor JA; Branfman AR; Liss RH; Yesair DW
Cancer Res; 1982 Feb; 42(2):627-32. PubMed ID: 7055806
[TBL] [Abstract][Full Text] [Related]
3. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
Ardalan B; Kensler TW; Jayaram HN; Morrison W; Choie DD; Chadwick M; Liss R; Cooney DA
Cancer Res; 1981 Jan; 41(1):150-6. PubMed ID: 7448755
[TBL] [Abstract][Full Text] [Related]
4. Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.
White JC; Hines LH
Biochem Pharmacol; 1984 Nov; 33(22):3645-8. PubMed ID: 6508821
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
[TBL] [Abstract][Full Text] [Related]
6. A facile enzymatic technique for the estimation of nanomolar concentrations of N-phosphonacetyl-L-aspartic acid in plasma.
Kensler TW; Jayaram HN; Cooney DA
J Biochem Biophys Methods; 1980; 2(1):29-35. PubMed ID: 6999068
[TBL] [Abstract][Full Text] [Related]
7. Cooperative binding of the bisubstrate analog N-(phosphonacetyl)-L-aspartate to aspartate transcarbamoylase and the heterotropic effects of ATP and CTP.
Newell JO; Markby DW; Schachman HK
J Biol Chem; 1989 Feb; 264(5):2476-81. PubMed ID: 2644262
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of the interaction of N-(phosphonacetyl)-L-aspartate with the catalytic subunit of aspartate transcarbamoylase. A slow conformational change subsequent to binding.
Cohen RE; Schachman HK
J Biol Chem; 1986 Feb; 261(6):2623-31. PubMed ID: 3949739
[TBL] [Abstract][Full Text] [Related]
9. The binding of N-(phosphonacetyl)-L-aspartate to aspartate carbamoyltransferase of Escherichia coli.
Volź KW; Krause KL; Lipscomb WN
Biochem Biophys Res Commun; 1986 Apr; 136(2):822-6. PubMed ID: 3518720
[TBL] [Abstract][Full Text] [Related]
10. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
[TBL] [Abstract][Full Text] [Related]
11. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
Lankelma J; Penders PG; Leyva A; Kleeberg UR; Kenny JB; Bramwell V; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1199-204. PubMed ID: 7199467
[No Abstract] [Full Text] [Related]
12. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
[TBL] [Abstract][Full Text] [Related]
14. Role of endocytosis and lysosomal pH in uptake of N-(phosphonacetyl)-L-aspartate and its inhibition of pyrimidine synthesis.
White JC; Hines LH
Cancer Res; 1984 Feb; 44(2):507-13. PubMed ID: 6692357
[TBL] [Abstract][Full Text] [Related]
15. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
Friedman J; Moore EC; Hall SW; Loo TL
Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
Branfman AR; Bruni RJ; Merrill YN; Chadwick M; Strong JM; Ervin TJ
J Chromatogr; 1980 May; 182(2):163-9. PubMed ID: 7380909
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometric technique for the determination of N-phosphonoacetyl-L-aspartic acid in serum.
Roboz J; Suzuki R; Rose E
J Chromatogr; 1980 Feb; 181(2):195-205. PubMed ID: 7372753
[TBL] [Abstract][Full Text] [Related]
19. 2.5 A structure of aspartate carbamoyltransferase complexed with the bisubstrate analog N-(phosphonacetyl)-L-aspartate.
Krause KL; Volz KW; Lipscomb WN
J Mol Biol; 1987 Feb; 193(3):527-53. PubMed ID: 3586030
[TBL] [Abstract][Full Text] [Related]
20. Determination of N-(phosphonacetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography.
Lankelma J; Penders PG; Leyva A; Pinedo HM
Eur J Cancer (1965); 1980 Nov; 16(11):1483-7. PubMed ID: 7227423
[No Abstract] [Full Text] [Related]
[Next] [New Search]
